← BIOMARIN PHARMACEUTICAL INC BMRN
Market Price
$67.35
Market Cap
$13.24B
P/E Ratio
37.42
Revenue (FY 2025)
↑12.9% YoY
$3.22B
3-Yr CAGR: 15.4%
Net Income
↓-18.3% YoY
$348.90M
Net Margin: 10.8%
Free Cash Flow
↑48.7% YoY
$724.96M
FCF Yield: 5.48%
EPS (Diluted)
↓-18.6% YoY
$1.80
Basic: $1.82
Return on Equity
Efficiency
5.7%
ROA: 8.8%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (BMRN)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $1,116.9M | — | $907.2M | $-630.2M | — | $-3.81 | — | $-227.8M | $-376.2M | — |
| FY 2017 | $1,313.6M | +17.6% | $1,071.9M | $-117.0M | +81.4% | $-0.67 | +82.4% | $-8.8M | $-208.0M | +44.7% |
| FY 2018 | $1,491.2M | +13.5% | $1,175.9M | $-77.2M | +34.0% | $-0.44 | +34.3% | $20.2M | $-124.4M | +40.2% |
| FY 2019 | $1,704.0M | +14.3% | $1,344.6M | $-23.8M | +69.1% | $-0.13 | +70.5% | $48.3M | $-96.8M | +22.2% |
| FY 2020 | $1,860.5M | +9.2% | $1,336.2M | $859.1M | +3,702.4% | $4.53 | +3,584.6% | $85.4M | $-28.9M | +70.1% |
| FY 2021 | $1,846.3M | -0.8% | $1,375.8M | $-64.1M | -107.5% | $-0.35 | -107.7% | $304.5M | $209.0M | +821.9% |
| FY 2022 | $2,096.0M | +13.5% | $1,612.4M | $141.6M | +320.9% | $0.75 | +314.3% | $175.9M | $54.9M | -73.7% |
| FY 2023 | $2,419.2M | +15.4% | $1,904.4M | $167.6M | +18.4% | $0.87 | +16.0% | $159.3M | $62.6M | +13.9% |
| FY 2024 | $2,853.9M | +18.0% | $2,273.7M | $426.9M | +154.6% | $2.21 | +154.0% | $572.8M | $487.4M | +679.0% |
| FY 2025 | $3,221.3M | +12.9% | $2,503.8M | $348.9M | -18.3% | $1.80 | -18.6% | $828.0M | $725.0M | +48.7% |
Valuation
Market Price
$67.35
Market Cap
$13.24B
Enterprise Value
N/A
P/E Ratio
37.42
P/B Ratio
2.14
FCF Yield
5.48%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
77.73%
Operating Margin
12.71%
Net Margin
10.83%
Return on Equity (ROE)
5.73%
Return on Assets (ROA)
8.83%
Asset Turnover
0.81x
Revenue 3-Yr CAGR
15.40%
Financial Health & Liquidity
Current Ratio
5.21
Cash Ratio
1.73
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$1.31B
Total Debt
N/A
Book Value / Share
$31.49
Cash Flow Efficiency
Operating Cash Flow
$827.99M
Capital Expenditures (CapEx)
$103.04M
Free Cash Flow
$724.96M
OCF / Revenue
25.70%
FCF / Revenue
22.51%
FCF 3-Yr CAGR
136.30%
Per Share Metrics
EPS (Diluted)
$1.80
EPS (Basic)
$1.82
Dividends / Share
N/A
Book Value / Share
$31.49
EPS YoY Growth
-18.55%
Balance Sheet (FY 2025)
Total Assets
$3.95B
Total Liabilities
$759.03M
Stockholders' Equity
$6.09B
Current Assets
$3.95B
Current Liabilities
$759.03M